suministro del medicamento REBLOZYL (principio activo LUSPATERCEPT 25 MG vial polvo subcutanea, LUSPATERCEPT 75 MG vial polvo subcutanea) Y ZEPOSIA (principio activo OZANIMOD 0,92 MG capsula oral), con destino Servicio de Farmacia del Hospital Universitario Nuestra Señora de Candelaria

Contract type	Supplies
CPV	33690000
Awarded to	BRISTOL-MYERS SQUIBB, S.A.U.

Full tender details, bidder list, market context and related contracts available below. Data sourced from TED — the Official Journal of the EU.